Breakeven Is Near for CorMedix Inc. (NASDAQ:CRMD)

With the business potentially at an important milestone, we thought we'd take a closer look at CorMedix Inc.'s (NASDAQ:CRMD) future prospects. CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. On 31 December 2024, the US$500m market-cap company posted a loss of US$18m for its most recent financial year. As path to profitability is the topic on CorMedix's investors mind, we've decided to gauge market sentiment. Below we will provide a high-level summary of the industry analysts’ expectations for the company.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

CorMedix is bordering on breakeven, according to the 6 American Pharmaceuticals analysts. They expect the company to post a final loss in 2024, before turning a profit of US$48m in 2025. The company is therefore projected to breakeven around 12 months from now or less. At what rate will the company have to grow in order to realise the consensus estimates forecasting breakeven in under 12 months? Using a line of best fit, we calculated an average annual growth rate of 37%, which is rather optimistic! Should the business grow at a slower rate, it will become profitable at a later date than expected.

Underlying developments driving CorMedix's growth isn’t the focus of this broad overview, though, take into account that generally pharmaceuticals, depending on the stage of product development, have irregular periods of cash flow. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.

Check out our latest analysis for CorMedix

One thing we’d like to point out is that CorMedix has no debt on its balance sheet, which is quite unusual for a cash-burning pharma, which usually has a high level of debt relative to its equity. The company currently operates purely off its shareholder funding and has no debt obligation, reducing concerns around repayments and making it a less risky investment.

Next Steps:

This article is not intended to be a comprehensive analysis on CorMedix, so if you are interested in understanding the company at a deeper level, take a look at CorMedix's company page on Simply Wall St. We've also compiled a list of pertinent aspects you should look at:

1. Valuation: What is CorMedix worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether CorMedix is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on CorMedix’s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.